The risk of developing active tuberculosis associated with a different size of induration to purified protein derivative (PPD) has not been prospectively assessed among individuals infected with human immunodeficiency virus (HIV).
The quantification of this risk is important to more appropriately identify candidates for preventive therapy for tuberculosis.
A prospective, multicenter, cohort study on tuberculosis in HIV-infected patients was conducted in 23 infectious disease units in public hospitals in Italy.
Two thousand six hundred ninety-five HlV-infected patients were enrolled in the study.
Of these, 1054 patients who were nonanergic at the time of entry were included in the present analysis.
The median duration of follow-up was 102 weeks.
The main outcome measure was a diagnosis of active tuberculosis confirmed by the isolation of Mycobacterium tuberculosis in culture.
Among the 252 patients with PPD reactivity, patients with an induration to PPD of 2 to 4 mm had a median CD4+lymphocyte count of 0.34 x 109/L (interquartile [IQ] range, 0.14x 109-0.56X109), those with a response of 5 to 9 mm had a median count of 0.38x109/L (IQrange, 0.24X1090.56 X109), and those with a response of 10 mm or higher had a median count of 0.37X109/L (IQ range, 0.23x109-0.52X109) (P=38).
Compared with the 802 nonanergic PPD-negative patients, hazard ratios of tuberculosis were 2.1 (95% confidence interval [CI], 0.2-18. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Association, Tuberculose, Mycobactériose, Bactériose, Facteur risque, Evaluation, Tuberculine PPD, Prospective, Etude cohorte, Prévention, Homme, Immunopathologie, Immunodéficit, Organisation santé, Immunoprophylaxie
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Association, Tuberculosis, Mycobacterial infection, Bacteriosis, Risk factor, Evaluation, Tuberculin PPD, Prospective, Cohort study, Prevention, Human, Immunopathology, Immune deficiency, Public health organization, Immunoprophylaxis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0256130
Code Inist : 002B06D01. Création : 11/06/1997.